Guide

Does beta-glucan help gut health? What the trials found

Beta-glucan trials split cleanly into two groups that are often conflated: trials measuring lab markers — fecal short-chain fatty acids, gut bacteria ratios, colonic transit time — and the much rarer trials measuring whether people actually felt fewer digestive symptoms. The two symptom trials that exist used ingredients different from the plain oat or barley beta-glucan sold in most supplements, and the largest, best-controlled trial found no symptom benefit at all.

What "beta-glucan" means here

Beta-glucan is a soluble fiber found in oat and barley bran, and a structurally different form is also extracted from mushrooms and yeast cell walls. The trials below use several different sources — oat, barley, and a Schizophyllum commune mushroom extract called TBG-136 — and one uses a proprietary mixture of beta-glucan plus inositol and digestive enzymes rather than beta-glucan alone. These are not interchangeable, and a result from one source or format doesn't transfer to another.

The strongest constipation result used a mushroom extract, not oat fiber

A randomized, double-blind, placebo-controlled trial gave 80 constipated adults (40 per group, 74 completed) either 80 mg/day of TBG-136 or a placebo for 8 weeks. The TBG-136 group had significantly better rectosigmoid colonic transit time and more defecations than placebo (p=0.011), significantly more Lactobacillus (p<0.05), and a bigger improvement on a living-with-constipation quality-of-life index at 8 weeks (p=0.043) (Kim et al., Journal of Functional Foods). This is a real, well-controlled result — but at a dose (80 mg) roughly 40 times smaller than the 3 g used in most oat beta-glucan research, and from an ingredient not found in typical oat-fiber supplements.

The largest, best-controlled symptom trial found nothing

The BELT Study gave 83 Italian adults 3 g/day of oat beta-glucan (as the OatWell-based Beta Heart ingredient) or an isocaloric placebo in a double-blind, placebo-controlled crossover over two 2-month periods, with 89% compliance. It tracked self-perceived intestinal well-being — weekly defecations, stool consistency, ease and completeness of expulsion, abdominal discomfort, and swelling — at 4 and 8 weeks. None of those measures differed significantly from placebo (p values ranged from 0.26 to 0.92). The same trial did significantly lower LDL cholesterol, by 12.2% at 4 weeks and 15.1% at 8 weeks (both p<0.01), which was its actual primary purpose; three subjects had moderate abdominal discomfort and one had dysphagia (Cicero et al., Nutrients, 2020).

Higher doses mean more side effects, not more benefit

A 263-person, double-blind, placebo-controlled trial tested oat beta-glucan tablets at 1.5 g, 3 g, and 6 g per day against placebo for 12 weeks in adults with high LDL cholesterol. LDL didn't improve significantly at any dose (p=0.23, 0.18, and 0.72). Gastrointestinal adverse events, though, rose with dose: 23.4% at 1.5 g/day, 34.8% at 3 g/day, and 66.7% at 6 g/day, all above the 36.9% seen with placebo (p<0.0001 overall) (Rioux-Labrecque et al., American Journal of Clinical Nutrition, 2023). More beta-glucan made tolerability worse without making anything measurably better.

Lab markers do move — without a symptom read-out

Two trials show beta-glucan changes fermentation and bacterial composition at 3 g/day, without ever asking whether people felt different. In a 48-person, double-blind trial in gastritis patients, 30 days of oat beta-glucan significantly raised fecal acetic, propionic, and hydroxybutyric acid (all p<0.0001 by ANOVA) versus placebo, and C-reactive protein fell in all groups (p<0.02) (Gudej et al., Nutrients, 2021). In a 30-person crossover trial, 3 g/day of high-molecular-weight barley beta-glucan increased Bacteroides from 5.96% to 12.26% of the gut community (p=0.002) and shifted overall bacterial composition (p=0.002), with no gastrointestinal symptom outcome measured at all (Wang et al., Frontiers in Microbiology, 2016). Both are genuine biological effects; neither tells you whether bloating, pain, or bowel habits changed.

The mixture trials aren't placebo-controlled

Two Italian trials tested "Biointol," a mixture of beta-glucan, inositol, and digestive enzymes, not beta-glucan alone. In 90 IBS patients (50 given Biointol, 40 given no therapy at all, not a placebo), Biointol was reported to significantly improve bloating, flatulence, and abdominal pain, with a slight increase in bowel urgency and no effect on other symptoms; no percentages or p-values were reported (Ciacci et al., Minerva Gastroenterologica e Dietologica, 2011). In 43 IBD patients in remission on mesalamine, adding Biointol (23 patients, versus 20 on mesalamine alone) was reported to reduce abdominal pain, bloating, and flatulence and improve general well-being, while the mesalamine-only group saw only a mild reduction in evacuation urgency; again, no percentages or p-values were reported on the page (Gianni et al., European Review for Medical and Pharmacological Sciences). Both compared active treatment against no added treatment rather than a matching placebo, so some of the reported improvement could reflect that patients knew they were getting something extra.

What a 2024 review concluded

A review of oat research across all health outcomes stated plainly that "clinical data for a potential gut barrier effect is lacking," while noting that oat beta-glucan does measurably increase fecal bulk (Mathews & Chu, Nutrients, 2024). That statement, from a reviewer independent of any single trial, matches what the individual trials above show: real, measurable effects on fiber bulk, fermentation byproducts, and bacterial ratios, but no consistent evidence that those changes translate into fewer digestive symptoms for a typical person without constipation.

Seven trials, side by side

What this means for choosing a supplement

If constipation specifically is the target, the one placebo-controlled trial with a real effect used 80 mg/day of a mushroom-derived beta-glucan (TBG-136) not commonly sold in mainstream oat-fiber products — check a label for that specific ingredient rather than "beta-glucan" generically. If the goal is general digestive symptoms or bloating, the best-controlled evidence (BELT) found no benefit from plain oat beta-glucan at 3 g/day, and the trials that did report symptom improvement weren't placebo-controlled. Oat and barley beta-glucan at 3 g/day reliably changes fecal chemistry and gut bacteria ratios, which may matter for reasons beyond daily symptoms, but going past 3 g/day up to 6 g/day has only been shown to add gastrointestinal side effects, not benefit.

Common questions

Sources

• Kim JH, et al. "TBG-136, a Schizophyllum commune-derived β-glucan benefits gut microbiota and intestinal health: A randomized, double-blind, and placebo-controlled clinical trial." Journal of Functional Foods, 2023. doi.org/10.1016/j.jff.2023.105668
• Cicero AFG, et al. "Middle-Term Effects of an Oat Beta-Glucan-Enriched Supplementation on Lipid Profile, Glycemia and Intestinal Health in Hypercholesterolemic Subjects: The BELT Study." Nutrients, 2020;12(4):1073. pmc.ncbi.nlm.nih.gov/articles/PMC7146517
• Rioux-Labrecque A, et al. "Effect of oat β-glucan tablets on LDL cholesterol and gastrointestinal tolerability." American Journal of Clinical Nutrition, 2023. Summarized at betaglucan.com/research
• Gudej S, et al. "Clinical Outcomes after Oat β-Glucans Dietary Treatment in Gastritis Patients." Nutrients, 2021;13(8):2791. pmc.ncbi.nlm.nih.gov/articles/PMC8400320
• Wang Y, et al. "High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk." Frontiers in Microbiology, 2016;7:129. pmc.ncbi.nlm.nih.gov/articles/PMC4748052
• Ciacci C, et al. "Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS." Minerva Gastroenterologica e Dietologica, 2011;57(4):325–330. pubmed.ncbi.nlm.nih.gov/21796867
• Gianni B, et al. "Effect of beta-glucan, inositol and digestive enzymes in IBD-IBS patients." European Review for Medical and Pharmacological Sciences. europeanreview.org/article/13006
• Mathews R, Chu Y. Review of oat research discussing beta-glucan and gut barrier function. Nutrients, 2024. pubmed.ncbi.nlm.nih.gov/39137936